Adempas (riociguat) / Bayer, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   17 Trials   17 Trials   785 News 


«12...3456789101112131415»
  • ||||||||||  Adempas (riociguat) / Bayer
    Safety of Riociguat in Patients Receiving Concomitant Prostanoids: Data from the EXPERT Registry (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area B) -  Mar 15, 2020 - Abstract #ATS2020ATS_10343;    
    P=N/A
    However, this may be a chance observation and the small sample size, more impaired disease state (70% and 54% of FC III and IV, respectively), and more complex pharmacology (prostanoids usually being prescribed third line) should be considered. The types of AE and SAE were as expected from the underlying disease and the profile of PH-targeted medication.
  • ||||||||||  Adempas (riociguat) / Bayer, Tyvaso (treprostinil) / United Therapeutics
    Pulmonary Hypertension Associated with T Cell Lymphoproliferative Disorders: An Insidious but Disastrous Complication (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area B) -  Mar 15, 2020 - Abstract #ATS2020ATS_9950;    
    Its implications are profound for combined immunosuppressant and vasodilator therapy which are safe to use in conjunction. The time course of this patient’s systemic illness calls into question the true prevalence of Large Granular Lymphocytic Leukemia and its consequences for pulmonary pathology while highlighting the need for a large-scale investigation into an LGLL population with the appropriate invasive diagnostic tests for PH.
  • ||||||||||  meropenem / Generic mfg., Daewon Pharmaceutical
    Acute Pulmonary Embolism Unmasking Chronic Thromboembolic Pulmonary Hypertension, Leading to Infraction, Lung Abscess and Empyema (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area K) -  Mar 15, 2020 - Abstract #ATS2020ATS_6742;    
    Low molecular weight heparin, meropenem and linezolid were also administered...The diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH) was confirmed, and the patient was treated with riociguat.DiscussionWe presented a rare case of acute pulmonary embolism in the context of newly diagnosed CTEPH, leading to pulmonary infraction, cavitation, lung abscess and empyema...Our patient improved significantly after thoracotomy and surgical resection of lung abscess.ConclusionAcute pulmonary embolism might result in infraction formation and subsequent lung abscess and empyema in predisposed subjects. An unrecognised diagnosis of CTEPH might complicate the clinical course of these patients.
  • ||||||||||  Adempas (riociguat) / Bayer
    Safety of Riociguat in Patients with Inoperable CTEPH and Persistent/Recurrent CTEPH: Data from the EXPERT Registry (PHILADELPHIA MARRIOTT DOWNTOWN, Grand Ballroom Salon B-D (Level 5)) -  Mar 15, 2020 - Abstract #ATS2020ATS_4037;    
    P=N/A
    Conclusions Baseline demographics, disease characteristics, and the safety profile of riociguat were similar in patients with inoperable CTEPH and those with persistent/recurrent CTEPH after PEA. The types of AE and SAE were as expected from the underlying disease and the known safety profile of riociguat and no new safety signals were observed.
  • ||||||||||  Adempas (riociguat) / Bayer
    Journal:  A Focus on Riociguat in the Treatment of Pulmonary Arterial Hypertension. (Pubmed Central) -  Feb 16, 2020   
    P3, P4
    Further investigations are needed to determine if this applies also to humans. Taken together, riociguat induces vasodilation of the pulmonary arteries and leads to an improvement in the ability to carry out physical activity.
  • ||||||||||  Adempas (riociguat) / Bayer, Merck (MSD)
    Enrollment closed:  PATENT-CHILD: Riociguat in Children With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) -  Dec 23, 2019   
    P3,  N=24, Active, not recruiting, 
    Riociguat treatment improved both clinical symptoms and pulmonary hemodynamics in the inoperative CTEPH patients in this study. Recruiting --> Active, not recruiting
  • ||||||||||  Adempas (riociguat) / Bayer
    Journal:  Soluble guanylate cyclase stimulators and activators: Where are we, where to go? (Pubmed Central) -  Dec 19, 2019   
    Notably, through activating the pathway, sGC stimulators and activators are potential therapies for the treatment of diverse diseases, such as PAH, heart failure (HF), diabetic nephropathy (DN) and systemic sclerosis (SS) as well as other diseases including sickle cell disease (SCD) and central nervous system (CNS) disease. Here, we review the preclinical and clinical studies of sGC stimulators and activators covering different diseases in recent five years and prospect the development of sGC modulators in the near future.
  • ||||||||||  Adempas (riociguat) / Bayer
    Activation of platelet Syk is regulated by a novel crosstalk between protein kinase C and Syk-serine phosphorylation  (Kaisen) -  Dec 17, 2019 - Abstract #GTH2020GTH_372;    
    Our data demonstrate that PKC activated by ITAM/Syk pathways stimulates Syk S297 phosphorylation and that this is a possible feedback regulation after Syk activation via GPIbα and GPVI. Thus, the S297 site within the crucial interdomain B, an important switch for Syk activation, might represent a potential diagnostic and/or therapeutic target in human platelets.
  • ||||||||||  Adempas (riociguat) / Bayer, University of Pittsburgh, Uptravi (selexipag) / J&J, Nippon Shinyaku, Opsumit (macitentan) / Nippon Shinyaku, J&J
    Journal:  New drugs, therapeutic strategies, and future direction for the treatment of Pulmonary Arterial Hypertension. (Pubmed Central) -  Oct 30, 2019   
    In this review, we discuss the use of newly-approved drugs for PAH treatment with already known mechanisms of action (macitentan), innovative targets (riociguat and selexipag), and novel therapeutic approaches with initial up-front combination therapy. Secondly, we describe new potential signalling pathways and investigational drugs with promising role in the treatment of PAH.
  • ||||||||||  Review, Journal:  Pharmacotherapy for pulmonary arterial hypertension. (Pubmed Central) -  Oct 22, 2019   
    Earlier clinical trials involving PAH-specific therapies evaluated improvements in 6-minute walk time as a primary improvement whereas contemporary trials have been larger and focused on morbidity and mortality reductions. While there may be a role for monotherapy in disease management, most patients should be considered for dual or triple therapy.
  • ||||||||||  Adempas (riociguat) / Bayer, University of Pittsburgh
    Journal:  Analysis of Oxygenation in Chronic Thromboembolic Pulmonary Hypertension Using Dead Space Ratio and Intrapulmonary Shunt Ratio. (Pubmed Central) -  Oct 12, 2019   
    For 11 of these 23 (10 were treated by balloon pulmonary angioplasty, one with riociguat), we also measured these parameters before and after CTEPH treatments...Although atrial oxygen saturation (SaO), DSR and ISR were improved (SaO: from 90.2 ± 3.2 to 93.7 ± 1.8%; DSR: from 0.64 ± 0.06 to 0.58 ± 0.04; ISR: from 0.20 ± 0.04 to 0.17 ± 0.02), these improvements were slight compared with that of mean pulmonary artery pressure.The DSR and ISR were abnormally elevated in patients with CTEPH and their improvement by treatment was limited. Only DSR can be a useful marker for normalization of hypoxia in CTEPH.
  • ||||||||||  Adempas (riociguat) / Bayer, University of Pittsburgh
    Journal:  Pulmonary Hypertension: Diagnostics, Classification and Therapy (Pubmed Central) -  Oct 8, 2019   
    In case of chronic thromboembolic pulmonary hypertension, the possibility of an operative pulmonary endarterectomy should be evaluated. To date, the only approved drug is Riociguat, a stimulator of the soluble guanylate cyclase.
  • ||||||||||  Adempas (riociguat) / Bayer, University of Pittsburgh
    Journal:  Druggability of Coronary Artery Disease Risk Loci. (Pubmed Central) -  Sep 28, 2019   
    Clinically, miR-199a/b is a novel target for the treatment of nitrate tolerance. Integration of genomic and pharmacological data may prove beneficial for drug repurposing and development, as evidence from our pipelines suggests.